>

Regeneron Pharmaceuticals Story

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>RE</div>
REGN -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Regeneron headline and social signals for Regeneron Pharmaceuticals on the 26th of December with financial sentiment analysis on the corporation that can be used to derive useful patterns or a particular trading strategy for Regeneron Pharmaceuticals. Additionally take a look at Regeneron Pharmaceuticals Hype Analysis, Regeneron Pharmaceuticals Correlation and Regeneron Pharmaceuticals Performance.
Exercise or conversion by Alfred Gilman of 5000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Filed transaction by Regeneron Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Regeneron Pharmaceuticals insider trading alert for exercise of non-qualified stock option (right to buy) by Alfred Gilman, the corporate stakeholder, on December 26, 2019. This event was filed by Regeneron Pharmaceuticals with SEC on 2014-02-12. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on December 26, 2019 was a factor to the next trading day price decrease.The trading delta at closing time against the next closing price was 0.41% . The trading delta at closing time when the story was published against the current closing price is 3.35% .

Similar stores for Regeneron Pharmaceuticals

few hours ago at MacroaxisInsider 
Payment of 6257 shares by Leonard Schleifer of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Payment of exercise price or tax liability by delivering or withholding securities
few days ago at MacroaxisInsider 
Purchase by Sanofi of 18945 shares of Regeneron Pharmaceuticals
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
six days ago at MacroaxisInsider 
Exercise or conversion by Shooter Eric M of 1572 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at MacroaxisInsider 
Sale by Leonard Schleifer of 450 shares of Regeneron Pharmaceuticals
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
over a week ago at MacroaxisInsider 
Sale by Michael Brown of 400 shares of Regeneron Pharmaceuticals
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
over two weeks ago at MacroaxisInsider 
Sale by George Yancopoulos of 200 shares of Regeneron Pharmaceuticals
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
over two weeks ago at MacroaxisInsider 
Exercise or conversion by Neil Stahl of 17182 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over three weeks ago at MacroaxisInsider 
Regeneron Pharmaceuticals exotic insider transaction detected
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. Unconventional Insider trading
over three weeks ago at MacroaxisInsider 
Exercise or conversion by Robert Terifay of 20000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at MacroaxisInsider 
Exercise or conversion by Neil Stahl of 50000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over two weeks ago at MacroaxisInsider 
Sale by Robert Landry of tradable shares of Regeneron Pharmaceuticals
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. General open market or private sale of non-derivative or derivative security
over a month ago at MacroaxisInsider 
Exercise or conversion by Michael Brown of 3240 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

  Probability Of Bankruptcy 
    
  Regeneron Pharmaceuticals Comparables 
Regeneron Pharmaceuticals is rated second in probability of bankruptcy category among related companies. For stocks, Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100 indicating the actual probability the firm will be distressed in the next 2 fiscal years.
Additionally take a look at Regeneron Pharmaceuticals Hype Analysis, Regeneron Pharmaceuticals Correlation and Regeneron Pharmaceuticals Performance. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Company logos by clearbit